Loading data for SDZ.SW — first visit, this takes a few seconds.

Sandoz Group AG (SDZ.SW)

Swiss: SDZ.SW · 实时价格 · USD

66.74

+0.68 (1.03%)

收盘价： Sep 11, 2026, 5:19 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

1.03% (1D)

买价	66.74
市值	28.9B
营收（TTM）	11.7B
净利润（TTM）	646M
	0.49
	1.19
	56.08
	17.87
市净率（TTM）	3.98
市销率（TTM）	2.47
财报日期	Feb 17, 2027

卖价	66.8
成交量	732,206
20日均量	833,897
开盘价	66.06
前收盘价	66.06
日内区间	65.68 - 68.00
52周区间	43.86 - 75.90
分析师	n/a
目标价	n/a
分红	$0.80 (1.21%)
除息日	Apr 13, 2026

关于 SDZ.SW

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage...

板块 Healthcare

上市日期 Oct 3, 2023

员工人数 20,000

交易所 Swiss

股票代码 SDZ.SW

官网 https://www.sandoz.com

公司完整简介

财务表现

2025年，Sandoz的营收为11.16B，较上一年的10.38B增长7.44%。净利润为914M，增长undefined%。

财务数据以CHF计财务报表

财报意外

Sandoz 已于 Invalid Date 发布季度财报：

营收为 n/a 低于预期 $0, ， NaN% 同比增长.
每股收益为低于预期 , ， NaN% 同比增长.

下次财报发布时间

Sandoz Group AG 的下次财报预计于 Feb 17, 2027, 盘中。
分析师预计营收为 ... 升级

股价变动原因

新闻

3周前 · BioPharma Dive

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

3周前 · The Wall Street Journal

Health Care Roundup: Market Talk

Find insights on Sandoz’s deal with Henlius, AstraZeneca and more in the latest Market Talks covering the health care sector.

3周前 · Pharmaceutical Technology

Sandoz targets industry patent void with $322m Henlius deal

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

1月前 · GuruFocus.com

Sandoz Group AG (SDZNY) (H1 2026) Earnings Call Highlights: Biosimilar Growth Drives 5% Sales ...

Strong biosimilar performance and strategic launches offset pricing pressures, boosting core EPS by 17%.

1月前 · The Wall Street Journal

Sandoz in Talks With U.S. Government About Potential Investment, CEO Says

Sandoz Group is in talks with the U.S. government about manufacturing investments in the country and doesn’t see President Trump’s planned tariffs on generic medicines as a major threat, the drugmaker...

第 1 页，共 2 页

Sandoz Group AG (SDZ.SW)